Camden National Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

Camden National Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$5.88M	Buy	+27,364	New	+$6.01M	1.17%	41

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Camden National Corporation's VRTX Position: Q1 2021 in Review

Camden National Corporation opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2021: 27,364 shares worth $5.88M. The stake represents 1.17% of the portfolio and ranks #41 among its holdings.

1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

Camden National Corporation held 27,364 shares of Vertex Pharmaceuticals worth $5.88M as of Q1 2021.
Vertex Pharmaceuticals was a new Camden National Corporation position in Q1 2021.
Vertex Pharmaceuticals made up 1.17% of Camden National Corporation's portfolio in Q1 2021, its #41 holding.
1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Camden National Corporation's 13F filing for Q1 2021, filed 12 May 2021.